ReviewFrontiers in immunology2025
Cytokine networks and therapeutic advances in systemic lupus erythematosus.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Ultrasensitive quantification of serum IL-5 in systemic lupus erythematosus does not reveal utility as a biomarker for disease activity or damage.Journal of translational autoimmunity · 2026Article
- Cytokine Gene Polymorphisms Modulate Isohemagglutinin Titers and Classes: Another Aspect Towards the Link Between ABO Groups and Human Pathologies?International journal of molecular sciences · 2026Article
- Immune network dysregulation in rheumatoid arthritis and systemic lupus erythematosus: cytokine signatures, autoantibody profiles, and implications for precision medicine.Frontiers in medicine · 2026Article
- Association of metabolic and inflammation vulnerabilities with systemic lupus erythematosus: a prospective UK Biobank study.Frontiers in immunology · 2026Article
- Stem cell-derived extracellular vesicles as immunomodulatory agents: targeting pathological crosstalk in systemic lupus erythematosus and multiple sclerosis.Frontiers in medicine · 2026Review
- Global perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the loss of immune tolerance, leading to the production of autoantibodies and widespread organ damage. Th1, Th2, and Th17 cytokines play critical roles in driving inflammation and tissue injury in SLE. IL-17 and IL-23 have been identified as key mediators in disease progression, with ongoing clinical trials assessing the efficacy of their inhibitors. Additionally, cytokines like IL-10 and IL-22 exhibit dual roles, influencing both pathogenic and protective immune responses. While targeted therapies have shown clinical promise, challenges related to safety and long-term efficacy persist. Emerging targets such as MIF and IL-39 offer new insights into disease mechanisms. This review summarizes the immunoregulatory functions of these cytokines, focusing on their contributions to disease pathogenesis and potential therapeutic strategies, highlighting the importance of cytokine in SLE treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.